Hippocampus Gene Expression Correlates for LM_CUE_ACTIVITY measured in BXD RI Females obtained using GeneNetwork Hippocampus Consortium M430v2 (Jun06) RMA. The LM_CUE_ACTIVITY measures Activity in altered context during presentation of cue under the domain Basal Behavior. The correlates were thresholded at a p-value of less than 0.001.
Authors:
Philip VM, Duvvuru S, Gomero B, Ansah TA, Blaha CD, Cook MN, Hamre KM, Lariviere WR, Matthews DB, Mittleman G, Goldowitz D, Chesler EJ
Hippocampus Gene Expression Correlates for LM_CUE_SUPPRESS measured in BXD RI Females obtained using GeneNetwork Hippocampus Consortium M430v2 (Jun06) RMA. The LM_CUE_SUPPRESS measures Suppression of activity in altered context under the domain Basal Behavior. The correlates were thresholded at a p-value of less than 0.001.
Authors:
Philip VM, Duvvuru S, Gomero B, Ansah TA, Blaha CD, Cook MN, Hamre KM, Lariviere WR, Matthews DB, Mittleman G, Goldowitz D, Chesler EJ
Whole Brain Gene Expression Correlates for ZM_LATENCY measured in BXD RI Females & Males obtained using INIA Brain mRNA M430 (Jun06) RMA. The ZM_LATENCY measures Zero Maze - Latency to enter an open quadrant under the domain Basal Behavior. The correlates were thresholded at a p-value of less than 0.001.
Authors:
Philip VM, Duvvuru S, Gomero B, Ansah TA, Blaha CD, Cook MN, Hamre KM, Lariviere WR, Matthews DB, Mittleman G, Goldowitz D, Chesler EJ
Striatum Gene Expression Correlates for VERCNT135 measured in BXD RI Males obtained using GeneNetwork Striatum M430V2 (Apr05) RMA. The VERCNT135 measures Morphine vertical activity counts minutes 120-135 under the domain Morphine. The correlates were thresholded at a p-value of less than 0.001.
Authors:
Philip VM, Duvvuru S, Gomero B, Ansah TA, Blaha CD, Cook MN, Hamre KM, Lariviere WR, Matthews DB, Mittleman G, Goldowitz D, Chesler EJ
Striatum Gene Expression Correlates for VERCNT165 measured in BXD RI Males obtained using GeneNetwork Striatum M430V2 (Apr05) RMA. The VERCNT165 measures Morphine vertical activity counts minutes 150-165 under the domain Morphine. The correlates were thresholded at a p-value of less than 0.001.
Authors:
Philip VM, Duvvuru S, Gomero B, Ansah TA, Blaha CD, Cook MN, Hamre KM, Lariviere WR, Matthews DB, Mittleman G, Goldowitz D, Chesler EJ
QTL for cocaine seizure on Chr14 at NA (38.23 Mbp , Build 37)
Description:
cocaine seizure spans 13.23 - 63.23 Mbp (NCBI Build 37) on Chr14. This interval was obtained by using an interval width of 25 Mbp around the peak marker (Build 37, MGI, http://informatics.jax.org).
QTL for nicotine sensitivity on Chr14 at D14Mit155 (49.05 Mbp , Build 37)
Description:
nicotine sensitivity spans 24.05 - 74.05 Mbp (NCBI Build 37) on Chr14. This interval was obtained by using an interval width of 25 Mbp around the peak marker (Build 37, MGI, http://informatics.jax.org).
QTL for METH responses for home cage activity on Chr14 at Gnrh (75.38 Mbp , Build 37)
Description:
METH responses for home cage activity spans 50.38 - 100.38 Mbp (NCBI Build 37) on Chr14. This interval was obtained by using an interval width of 25 Mbp around the peak marker (Build 37, MGI, http://informatics.jax.org).
QTL for chronic alcohol withdrawal severity on Chr14 at D14mit160 (75.81 Mbp , Build 37)
Description:
chronic alcohol withdrawal severity spans 50.81 - 100.81 Mbp (NCBI Build 37) on Chr14. This interval was obtained by using an interval width of 25 Mbp around the peak marker (Build 37, MGI, http://informatics.jax.org).
Authors:
Bergeson SE, Kyle Warren R, Crabbe JC, Metten P, Gene Erwin V, Belknap JK
QTL for METH responses for climbing on Chr14 at Es10 (78.19 Mbp , Build 37)
Description:
METH responses for climbing spans 53.19 - 103.19 Mbp (NCBI Build 37) on Chr14. This interval was obtained by using an interval width of 25 Mbp around the peak marker (Build 37, MGI, http://informatics.jax.org).
QTL associated with B.burgdorferi-associated arthritis 21. This interval was obtained by using a fixed interval width of 25 Mbp around the peak marker (60447235)
Authors:
Roper RJ, Weis JJ, McCracken BA, Green CB, Ma Y, Weber KS, Fairbairn D, Butterfield RJ, Potter MR, Zachary JF, Doerge RW, Teuscher C
GeneWeaver